日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort

SPIROMICS 队列中尿液线粒体 DNA 与 COPD 临床指标的关联

William Z Zhang, Michelle C Rice, Katherine L Hoffman, Clara Oromendia, Igor Z Barjaktarevic, J Michael Wells, Annette T Hastie, Wassim W Labaki, Christopher B Cooper, Alejandro P Comellas, Gerard J Criner, Jerry A Krishnan, Robert Paine 3rd, Nadia N Hansel, Russell P Bowler, R Graham Barr, Stephen

Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria

硝基咪唑-噁唑烷酮缀合物对厌氧菌的协同活性

Zhijun Zhuang ,Dawei Wan ,Jun Ding ,Shijie He ,Qian Zhang ,Xiaomei Wang ,Ying Yuan ,Yu Lu ,Charles Z Ding ,Anthony Simon Lynch ,Anna M Upton ,Christopher B Cooper ,William A Denny ,Zhenkun Ma

Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis

(6R)-2-硝基-6-[4-(三氟甲氧基)苯氧基]-6,7-二氢-5H-咪唑并[2,1-b][1,3]噁嗪 (DNDI-8219) 的开发:内脏利什曼病的新先导化合物

Andrew M Thompson ,Patrick D O'Connor ,Andrew J Marshall ,Adrian Blaser ,Vanessa Yardley ,Louis Maes ,Suman Gupta ,Delphine Launay ,Stephanie Braillard ,Eric Chatelain ,Baojie Wan ,Scott G Franzblau ,Zhenkun Ma ,Christopher B Cooper ,William A Denny

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis

7-取代的2-硝基-5,6-二氢咪唑并[2,1-b][1,3]噁嗪:新型抗结核药物,为内脏利什曼病提供了一种新的临床前候选药物

Andrew M Thompson ,Patrick D O'Connor ,Andrew J Marshall ,Vanessa Yardley ,Louis Maes ,Suman Gupta ,Delphine Launay ,Stephanie Braillard ,Eric Chatelain ,Scott G Franzblau ,Baojie Wan ,Yuehong Wang ,Zhenkun Ma ,Christopher B Cooper ,William A Denny

A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart

CELF和MBNL蛋白的出生后转换会重编程发育中心脏的替代剪接。

Kalsotra, Auinash; Xiao, Xinshu; Ward, Amanda J; Castle, John C; Johnson, Jason M; Burge, Christopher B; Cooper, Thomas A